BioMarin Submits Pegvaliase Biologics License Application (BLA) to the U.S. FDA for Treatment of Phenylketonuria (PKU)

SAN RAFAEL, Calif., June 30, 2017 -- (Healthcare Sales & Marketing Network) -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced that the company submitted a Biologics License Application (BLA) on Friday, June 30, 2017 to the U.S. Food and Drug Admini... Biopharmaceuticals, FDA BioMarin Pharmaceutical, pegvaliase, Phenylketonuria
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news